A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Participants with Relapsed/Refractory Hematologic Malignancies

• Research type

  Research Study

• Full title

  A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 in Participants with Relapsed/Refractory Hematologic Malignancies

• IRAS ID

  1007370

• Contact name

  Thomas Haberberger

• Contact email

  thaberberger@preludetx.com

• Sponsor organisation

  Prelude Therapeutics

• Eudract number

  2022-502672-23

• Clinicaltrials.gov Identifier

  NCT05665530

• Research summary

  The purpose of this clinical research study is to test the safety of PRT2527 at different dose levels to find out what effects, good and/or bad, PRT2527 has on participants and their type of cancer. The information collected from participants and from other patients in this study will be used to decide the most appropriate dose of PRT2527 that should be used for studies that may be completed in the future. Up to 51 male and female participants aged 18 and over will take part in this study. This study will take place at approximately 20 study centres globally.

• REC name

  London - Brent Research Ethics Committee

• REC reference

  23/HRA/2630

• Date of REC Opinion

  19 Sep 2023

• REC opinion

  Further Information Favourable Opinion